Skip to content
Food and Drug Administration (FDA) inaction on patents for drug delivery devices has been troubling drug manufacturers for 20 years, and the situation is […]
Sen. Cassidy calls on FDA to act, not abdicate, on drug device patents Read More »
Mpox has proven to be a major public threat since its resurgence globally during the COVID years. As Bio.News reported, “On Aug. 14, the
BIO speaks on Capitol Hill about mpox preparedness Read More »
With the 118th Congress wrapping up in a few months, the Biotechnology Innovation Organization (BIO) continues its work to improve policy that impacts the
What to know about BIO’s 7 Core Strategic Priorities Read More »
Going from “we have a problem” to “we have an idea” to “we have a solution” is an important journey for patient advocates and
Sen. Todd Young (R-IN) was recently named Chair of the National Security Commission on Emerging Biotechnology (NSCEB), established by Congress to recommend policy on biotech and national security.
A new suite of rules governing drug rebates in Medicaid has been finalized, removing months of uncertainty about whether the Centers for Medicare and
September is Sepsis Awareness Month, and the Biotechnology Innovation Organization (BIO) is partnering with Sepsis Alliance to spread the word about sepsis and provide
Sepsis Awareness Month: 3 things you need to know about sepsis Read More »
During a busy week in Congress, House legislation to support drug development for pediatric rare diseases moved forward with bipartisan support, and a Senate
Capitol Hill update: House advances PPRV reauthorization, Senate reviews IRA Read More »
Yesterday, Sen. Bernie Sanders held a meeting about the new class of groundbreaking diabetes and weight-loss medicines. Next week, he will hold a hearing
Market concentration allows pharmacy benefit managers (PBMs) to siphon off funds from our health care system while increasing costs to patients and reducing access
House hearing delves into antitrust problems of PBMs Read More »
